Maxim Group analyst Jason McCarthy assigned a Buy rating to Viking Therapeutics (VKTX) yesterday and set a price target of $14.00. The company’s shares closed last Friday at $6.46.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 37.8% and a 47.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $16.44, implying a 167.8% upside from current levels. In a report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
Viking Therapeutics’ market cap is currently $483.1M and has a P/E ratio of -11.50. The company has a Price to Book ratio of 1.97.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VKTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
